VXRT Vaxart
- 0.729
- -0.020-2.68%
- 0.742
- +0.013+1.78%
Vaxart News
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
PDF Version Antibody rise observed in lactating mothers and in their breast milkLong-term goal is to provide protection to infants through passive antibody transferSOUTH SAN FRANCISCO, Calif., April
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
PDF Version SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at t
Press Release: Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") tod
Buy Rating Affirmed for Vaxart Amid Promising Vaccine Trials and Strategic Advancements
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PDF Version SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that the Compensation Committee of the Board of D
Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT)
Earnings Call Summary | Vaxart(VXRT.US) Q4 2023 Earnings Conference
The following is a summary of the Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript:Financial Performance:Vaxart reported a revenue of $7.4 million in 2023, an increase compared to $0.1 million in
Vaxart Inc (VXRT) Reports Full Year 2023 Financial Results
Recap: Vaxart Q4 Earnings
Vaxart (NASDAQ:VXRT) reported its Q4 earnings results on Thursday, March 14, 2024 at 04:01 PM.Here's what investors need to know about the announcement.EarningsVaxart beat estimated earnings by 14.000
Vaxart GAAP EPS of -$0.57 Beats by $0.02, Revenue of $7.4M Beats by $2.19M
Vaxart 2023 Rev $7.38M >VXRT
Vaxart 2023 Rev $7.38M >VXRT
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
PDF Version Significant progress made in preparing for a Phase 2b study evaluating Vaxart's oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparatorTopline data from Phase 1 norovir
Vaxart's Earnings: A Preview
Vaxart (NASDAQ:VXRT) is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Here's what investors need to know before the announcement.Analysts estimate that Vaxart will report a
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
PDF Version Conference call to begin at 4:30 p.m. ETSOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and
Vaxart Names Steven Lo President, Chief Executive
By Colin Kellaher Vaxart has hired veteran biopharma executive Steven Lo as president and chief executive of the clinical-stage biotechnology company, effective March 18. Vaxart on Wednesday said Lo
Press Release: Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06,
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
PDF Version Michael J. Finney, Ph.D. to Continue as Chairman of the Board of DirectorsSOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "
Vaxart Inc Launches New Equity Plan to Attract Talent
VAXART, INC. (VXRT) Is a Great Momentum Stock: Should You Buy?
Vaxart Regains Compliance With Nasdaq Listing Standards
Analysis
Price Target
No Data
